Series B
$28M
HLB Innovation · Lead
Open roles0
Total raised$28M
Team size11-50
Founded · Stage2020 · Series B
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Verismo Therapeutics is a clinical-stage cell therapy company developing a multi-chain KIR-CAR platform that adapts NK-cell killer immunoglobulin-like receptor and DAP12 signaling to extend CAR T cell therapy beyond blood cancers into solid tumors. Founded by inventors of the Kymriah CAR-T (including Carl June), the company is advancing two Phase 1 programs: SynKIR-110 in mesothelin-positive solid tumors and SynKIR-310 in relapsed/refractory B cell non-Hodgkin lymphoma. It is a U.S. subsidiary of KOSDAQ-listed HLB Innovation.
Why it matters
Signals from funding, traction, and product direction.
- Investment was structured as a third-party allotment of newly issued shares: HLB Innovation acquired 5,283,018 new shares, lifting its ownership in Verismo from 98.75% to 98.93%.
- Financing was timed ahead of Verismo presenting first-ever KIR-CAR clinical data at AACR 2026 in the Late-Breaking Clinical Trials Plenary Session on April 20, 2026.
- Verismo was founded by the inventors of Kymriah, the first FDA-approved CAR-T therapy, including Carl June, Bryan Kim, Laura Johnson, Michael Milone, and Donald Siegel.
- Approximately KRW 41.4 billion in USD terms, capitalizing two parallel Phase 1 programs targeting both solid tumors (SynKIR-110) and hematologic cancers (SynKIR-310).
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Investors
HLB Innovation
Focus areas
BiotechnologyClinical TrialsHealthtechMedtechPharmaceuticals
No open roles on the board yet
We do not have indexed listings for Verismo Therapeutics right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts